Next-generation sequencing (NGS) technologies have revolutionised genomic research by decreasing the cost of sequencing while increasing the throughput. The focus now is on the clinical applications of NGS technology. Clinical application of NGS in cancer can detect clinically actionable genetic/genomic alterations that are critical for cancer care. In certain cancers, patient risk and prognosis can be predicted based on the mutation profile identified by NGS. Many targeted therapies have been developed for cancer patients who bear specific mutations. However, choosing the right NGS techniques for appropriate clinical applications can be challenging, especially in clinical oncology, where the material for testing is often limited and the turnaround time of testing is frequently constrained to just a few days. Currently, targeted NGS approaches have emerged as the best fit for clinical oncology.

Speakers

• Marilyn M. Li, MD

  Marilyn M. Li, MD, is the vice chief of the Division of Genomic Diagnostics with The Children’s Hospital of Philadelphia. She is also Professor of Pediatrics and Professor of Clinical Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine.

• Moderator: Dr Jayshan Carpen, NPG

  Jayshan received his Ph.D. in neurogenetics from the University of Surrey, UK. His doctoral thesis focused on identifying polymorphisms associated with diurnal preference and circadian sleep disorders. Jayshan worked as an events coordinator at the Royal Institution of Great Britain before moving to his current role in 2013 for Nature Publishing Group (NPG).

Register here